Mustang Bio Analyst Ratings
Analysts' Top Healthcare Picks: Mustang Bio (MBIO), TransCode Therapeutics (RNAZ)
HC Wainwright & Co. : The Mustang Bio (MBIO.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $25.00 to $2.00.
Mustang Bio Analyst Ratings
HC Wainwright & Co. Maintains Buy on Mustang Bio, Adjusts Price Target To $2
Mustang Bio Earns Buy Rating: Strong Financials and Promising Clinical Developments
Analysts Offer Insights on Healthcare Companies: ICAD (ICAD), Mustang Bio (MBIO) and Cerus (CERS)
BTIG Sticks to Its Buy Rating for Mustang Bio (MBIO)
Mustang Bio (MBIO) Gets a Buy From BTIG
Analysts' Top Healthcare Picks: Mustang Bio (MBIO), RAPT Therapeutics (RAPT)
Mustang Bio's Positive Financial Performance and Promising Clinical Developments Drive Buy Rating
Mustang Bio Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Mustang Bio, Maintains $25 Price Target
Mustang Bio Analyst Ratings
What 4 Analyst Ratings Have To Say About Mustang Bio
BTIG Maintains Buy on Mustang Bio, Lowers Price Target to $16
Mustang Bio Analyst Ratings
H.C. Wainwright Sticks to Their Buy Rating for Mustang Bio (MBIO)
HC Wainwright & Co. Reiterates Buy on Mustang Bio, Maintains $25 Price Target
H.C. Wainwright Remains a Buy on Mustang Bio (MBIO)
No Data